Oxford Immunotec (UK), Cellular Technology Limited (US) and Mabtech (Sweden) are Leading Players in the ELISpot and FluoroSpot Assay Market
The global ELISpot and FluoroSpot Assays Market is expected to reach USD 421 million by 2028 from USD 292 million in 2023, at a CAGR of 7.6% during the forecast period. The growth of this market is majorly driven by accelerating immunization development to address challenges of antimicrobial resistance. However, strict requirements for consent of ELISpot and FluoroSpot assay’ instruments and consumables is one of the challenges for which may obstruct the growth of this market.
The key players operating in this market are Oxford Immunotec USA, Inc. (Subsidiary of Revvity Inc.) (UK), Cellular Technology Limited (US), Mabtech (Sweden), Becton, Dickinson and Company (US), Abcam plc. (UK), Bio-Techne. (US), Mikrogen Diagnostik (Germany), Autoimmun Diagnostika GmbH (Germany), U-CyTech (Netherland), and Medix Biochemica (Finland).
To know about the assumptions considered for the study download the pdf brochure
Oxford Immunotec (UK)
Oxford Immunotec is among the top players in the ELISpot and FluoroSpot assays market. It is focused on the development of diagnostic kits for infectious diseases, tickborne diseases, and transplant-related infections. The company offers assay kits as well as testing services to its end users. The company’s ELISpot and FluoroSpot assay diagnostic kits offer a competitive edge over other competing technologies, such as ELISA, with higher sensitivity and single-cell qualitative and quantitative detection. The company has an extensive product portfolio based on various technologies. It has a strong presence across North America, Europe, Asia, and the Middle East, alongside a strong direct and indirect distribution network across the globe. With the increasing use of ELISpot kits for diagnosis, Oxford Immunotec is expected to maintain its leading position in the ELISpot and FluoroSpot assays market during the forecast period.
Cellular Technology Limited (US)
Cellular Technology Limited (CTL) is a global biotechnology company and a leading player in the ELISpot and FluoroSpot assays market. The company provides tools for specializing in standardized immune monitoring. It offers assay kits, analyzers, and ancillary products, such as serum-free media, antigens, and PBMCs, for this market. The analyzers offered by the company are made either specifically for ELISpot or are dual-purpose ELISpot and FluoroSpot analyzers with up to 12 color detection. The company has a presence in North and South America, Europe, the Asia Pacific, and the Rest of the World (Africa and the Middle East). Its subsidiaries include CTL-Europe (Germany) and CTL-China.
Mabtech (Sweden)
Mabtech is a global biotechnology company that specializes in the development and production of antibodies, kits, and reagents for immunology and cell biology research. The company has a strong presence in the field of enzyme-linked immunospot (ELISpot) and FluoroSpot assays, which are essential tools for studying immune responses. Mabtech is renowned for its comprehensive range of ELISpot and FluoroSpot kits and reagents. These kits are used for the detection and quantification of specific immune responses, including the production of cytokines, in various research applications. Mabtech’s products are used in a wide range of research areas, including immunology, infectious diseases, vaccine development, autoimmune diseases, and cancer immunotherapy.
Related Reports:
ELISpot and FluoroSpot Assay Market by Product (Assay kit (Technique, Utility, Analyte (T Cell and B Cell assay)), Analyzer), Application (Transplants, Infectious Diseases, Vaccine Development, Cancer Research), End User - Global Forecast to 2028
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
SEND ME A FREE SAMPLE
